Logo

Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study at ASH 2020

Share this

Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study at ASH 2020

Shots:

  • Nektar presents two nonclinical data presentations for NKTR-255 at the 62nd ASH Annual Meeting- which include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farber Cancer Center
  • NKTR-255 is being tested in a P-Ib/II study as monothx. & in combination with rituximab or daratumumab in patients with MM & NHL and being evaluated in a P-Ib/II trial in combination with cetuximab for the treatment of colorectal cancer & HNSCC
  • NKTR-255 is an IL-15 receptor agonist designed to activate the IL-15 pathway & expand NK cell- promoting the survival & expansion of memory CD8+ T cells without inducing suppressive regulatory T cells

 ­ Ref: PRNewswire | Image: The Street

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions